OTC Markets EXMKT - Delayed Quote USD

RVL Pharmaceuticals plc (RVLPQ)

0.0000
0.0000
(0.00%)
At close: May 7 at 4:00:00 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2022
12/31/2021
12/31/2020
Total Revenue
36,919
49,721
17,501
27,762
Cost of Revenue
9,330
9,456
3,618
3,293
Gross Profit
27,589
40,265
13,883
24,469
Operating Expense
71,161
85,945
94,393
86,211
Operating Income
-43,572
-45,680
-80,510
-61,742
Net Non Operating Interest Income Expense
-8,518
-253
-4,018
-4,095
Other Income Expense
-16,453
-5,779
1,994
-28,958
Pretax Income
-68,543
-51,712
-82,534
-94,795
Tax Provision
-277
-20
315
-5,782
Net Income Common Stockholders
-68,266
-51,692
-64,920
-79,589
Diluted NI Available to Com Stockholders
-68,266
-51,692
-64,920
-79,589
Basic EPS
-0.71
-0.58
-0.96
-1.31
Diluted EPS
-0.71
-0.58
-0.96
-1.31
Basic Average Shares
97,702.4960
89,797.3570
67,354.3360
60,652.9990
Diluted Average Shares
97,702.4960
89,797.3570
67,354.3360
60,652.9990
Total Operating Income as Reported
-70,782
-58,990
-82,754
-90,652
Total Expenses
80,491
95,401
98,011
89,504
Net Income from Continuing & Discontinued Operation
-68,266
-51,692
-64,920
-79,589
Normalized Income
-44,954.5897
-39,655.8164
-85,277.7100
-61,875.1830
Interest Income
--
2,857
--
--
Interest Expense
11,375
3,110
4,018
4,095
Net Interest Income
-8,518
-253
-4,018
-4,095
EBIT
-57,168
-48,602
-78,516
-90,700
EBITDA
-56,786
-48,227
-70,341
-69,674
Reconciled Cost of Revenue
9,330
9,456
3,618
3,293
Reconciled Depreciation
382
375
8,175
21,026
Net Income from Continuing Operation Net Minority Interest
-68,266
-51,692
-82,849
-89,013
Total Unusual Items Excluding Goodwill
-23,406
-12,041
3,327
-28,910
Total Unusual Items
-23,406
-12,041
3,327
-28,910
Normalized EBITDA
-33,380
-36,186
-73,668
-40,764
Tax Rate for Calcs
0
0
0.0003
0.0001
Tax Effect of Unusual Items
-94.5897
-4.8164
898.2900
-1,772.1830
12/31/2020 - 10/18/2018

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

BXRXQ Baudax Bio, Inc.
0.0000
0.00%
 
EMMA Emmaus Life Sciences, Inc.
0.0120
-7.69%
 
MCET MultiCell Technologies, Inc.
0.0000
0.00%
 
ELOX Eloxx Pharmaceuticals, Inc.
0.0001
0.00%
 
AIBT Aibotics Inc.
0.0220
+4.76%
 
KRBPQ Kiromic BioPharma, Inc.
0.1100
0.00%
 
GDTC CytoMed Therapeutics Limited
2.2201
-6.72%
 
MOLN Molecular Partners AG
4.1000
-0.97%
 
TCON TRACON Pharmaceuticals, Inc.
0.0322
0.00%
 
FNCH Finch Therapeutics Group, Inc.
13.50
+4.25%